The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
April 17th 2025
Though the rate of coronary artery lesions decreased across both cohorts of this trial of children with Kawasaki disease, there were no differences in lesion reduction between those receiving intravenous immunoglobulin (IVIG) alone and those receiving IVIG with aspirin.
Pharmacy-Based Clinical Trial Recruitment: A Potential New Role for the Pharmacist?
July 2nd 2013Research presented on June 25, 2013, at the Drug Information Association (DIA) 2013 49th Annual Meeting could trigger a paradigm shift in clinical trial patient recruitment and could change the way pharmacists engage with patients as new drugs make their way through the FDA approval process.
Read More
Diplomat Specialty Pharmacy Receives Compounding Pharmacy Accreditation from PCAB
June 27th 2013Diplomat Specialty Pharmacy, the country's largest independent specialty pharmacy servicing the needs of patients and physicians nationwide, is pleased to announce the company's compounding pharmacy has been accredited by the Pharmacy Compounding Accreditation Board (PCAB).
Read More
Avella Specialty Pharmacy: Overcoming Oncology Adherence Barriers
June 18th 2013Specialty Pharmacy Times sat down to talk with Dr. Eric Sredzinski about the controversial topic of pricing for oncology medications, as well as common patient reimbursement hurdles and Avella's technologically savvy efforts to break down patient adherence barriers.
Read More
DIA Spotlights Hot Topics in Drug Development and Regulation
June 17th 2013Patient engagement, financial backing, and personalized medicine-3 of the most pressing issues in drug development and regulatory affairs-will be discussed at length at the DIA 2013 49th Annual Meeting, June 23-27 in Boston.
Read More
Site-of-Care Optimization Under the Medical Benefit
June 15th 2013Michael Einodshofer, director, utilization management, Walgreens, describes how contractual methodologies and cost differences across various sites of service can influence how a specialty drug is reimbursed under the medical benefit.
Watch
FDA Approves Xgeva for Adults with Giant Cell Tumor of Bone
June 13th 2013The FDA today approved denosumab (Xgeva injection, for subcutaneous use) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Read More
Aetna and Cardinal Health Specialty Solutions Alliance to Share Best Practices at AHIP
June 12th 2013At the Association for Health Insurance Plan's (AHIP) conference this Thursday, medical directors from Cardinal Health Specialty Solutions and Aetna will provide expert insight into how collaboration between payers and physicians can directly lead to better cancer care that is more effective and costs less.
Read More
CVS Caremark Receives URAC Accreditation in Specialty Pharmacy
June 11th 2013CVS Caremark announced today that it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
Read More
Governor Kitzhaber Signs Legislation to Create Pathway for Substitution of Biologic Drugs
June 7th 2013The Biotechnology Industry Organization (BIO) and Oregon Bioscience Association (Oregon Bio) commend Oregon Governor John Kitzhaber for signing legislation designed to address the regulatory issues related to the interchangeability of biological medicines.
Read More
Illinois Strikes Down Biosimilar Legislation
June 6th 2013Illinois is now the 13th state to avoid enacting legislation that would slow patient access to biosimilars, which are new, affordable versions of costly brand biologic medicines that treat cancer, immune disorders and other complex diseases.
Read More